Mild-to-moderate active luminal Crohn's disease

Area of Science:

• Gastroenterology
• Inflammatory Bowel Disease

Background:

• Luminal Crohn's disease is the most common initial presentation.
• Mild-to-moderate disease and associated perianal disease affect a significant patient proportion.
• Patient quality of life correlates inversely with disease activity, necessitating adequate therapy.

Purpose of the Study:

• To review current management strategies for mild-to-moderate luminal Crohn's disease.
• To assess the efficacy of available treatments and identify areas for further research.

Main Methods:

• Literature review of existing treatment guidelines and clinical studies.
• Analysis of therapeutic options including sulfasalazine, budesonide, systemic steroids, mesalazine, and antibiotics.
• Evaluation of the current evidence for biological therapies in mild Crohn's disease.

Main Results:

• Sulfasalazine, budesonide, and systemic steroids are primary treatment options.
• The efficacy of mesalazine and antibiotics for luminal Crohn's disease remains controversial.
• Biological therapies have not been extensively evaluated in mild Crohn's disease patients.

Conclusions:

• Current treatment for mild-to-moderate luminal Crohn's disease focuses on established therapies.
• Further research is needed to clarify the role of mesalazine, antibiotics, and biologicals in this patient population.
• Effective management is key to improving the quality of life for patients with luminal Crohn's disease.